Natera, Aveta Biomics collaborate on head and neck cancer trial

Natera and Aveta Biomics Partner for Phase III Head and Neck Cancer Trial

Natera and Aveta Biomics have partnered for the AVTA 30-01, a global Phase III clinical trial assessing APG-157, an oral immunotherapy, in patients with locally advanced head and neck squamous cell carcinoma. The study aims to recruit approximately 826 participants across Australia, Asia-Pacific, Europe, and North America. Natera's Signatera test will be utilized as a secondary endpoint to measure molecular residual disease (MRD) and observe treatment responses. Patient enrolment for the trial is scheduled to commence in the second half of 2026, building on positive safety and efficacy data from prior Phase II studies.

• The AVTA 30-01 study is designed as a global Phase III trial, planning to recruit around 826 participants across multiple continents including Australia, Asia-Pacific, Europe, and North America. The trial incorporates separate randomized groups to evaluate APG-157 in both resectable and unresectable locally advanced cases, each featuring distinct treatment and control arms.
• APG-157, the investigational drug, is an oral immunotherapy that has already secured fast track and orphan drug designations from the US Food and Drug Administration (FDA) for head and neck squamous cell carcinoma. The drug is being explored for its potential to activate anti-tumour immunity in both immune-cold and immune-hot tumours.
• Natera's Signatera test will serve as a secondary endpoint in the AVTA 30-01 study, focusing on measuring molecular residual disease (MRD) and monitoring treatment responses throughout the therapy and follow-up periods. This integration is supported by successful Phase II clinical data and the SINERGY trial, which previously validated the utility of Signatera MRD-guided treatment in this cancer type.

Tackling Recurrence Risks in Locally Advanced Head and Neck Cancer

Despite decades of therapeutic advancement, head and neck squamous cell carcinoma (HNSCC) continues to carry a sobering prognosis, with recurrence rates ranging from 10% to 50% following curative-intent therapy. Conventional multimodal approaches — surgery, radiotherapy, and chemotherapy — have yielded only marginal improvements in survival, while introducing substantial toxicity burdens that further compromise patient quality of life. The persistence of these gaps underscores the urgent need to reassess the structural limitations embedded in current treatment paradigms.

• High recurrence and poor post-recurrence prognosis: Despite curative-intent therapy, 10%–50% of patients experience recurrence, and approximately one-third of radiotherapy-treated patients experience locoregional relapse within five years. Prognosis for recurrent or metastatic disease remains poor, with median overall survival between 4 and 6 months and limited salvage options available.

• Cisplatin resistance as a primary driver of treatment failure: Cisplatin remains the first-line chemotherapeutic agent in HNSCC, yet treatment failure frequently occurs due to acquired drug resistance. More broadly, agents including docetaxel, doxorubicin, and 5-fluorouracil are limited by non-specificity, resistance mechanisms, and systemic toxicity — and increased response rates have historically not translated into meaningful survival improvements.

• Inadequacy of clinical and pathologic risk stratification: Risk stratification based solely on clinical and pathologic criteria has proved insufficient, as tumors vary substantially in their molecular and genetic etiology. Critically, molecular deregulation is often already present in histopathologically normal tissue, rendering conventional staging frameworks unable to capture the full extent of disease biology.

• Therapy resistance mediated by the tumor microenvironment: Cancer-associated fibroblasts (CAFs) — among the most prominent cell types in the HNSCC tumor microenvironment — play a central role in therapy resistance. CAFs survive single-dose radiotherapy up to 68 Gy and fractionated doses of 3×8 Gy, entering senescence rather than undergoing apoptosis, while retaining pro-tumorigenic properties. The CAF secretome continues to enhance HNSCC cell proliferation and migration even post-irradiation.

• Late-stage diagnosis limiting therapeutic responsiveness: A substantial proportion of patients present at middle or advanced stage, at which point tumors are poorly responsive to standard treatment. Combined chemoradiation, while shown to improve locoregional control in unresectable disease, carries significantly greater toxicity, and there remains no clear demonstration of overall survival benefit from adding chemotherapy to locoregional therapy in resectable disease.

• Compounding challenges in older patient populations: The majority of older HNSCC patients present with locally advanced disease, and treatment planning is further complicated by comorbidities, frailty, functional impairment, and disabilities. Therapeutic decisions in this population require multidisciplinary input, and the evidence base from older-specific studies remains insufficient to guide definitive, individualized treatment selection while avoiding high toxicity and functional deterioration.

AVTA 30-01: Designing a Global Phase III Trial with Signatera

The HNSCC clinical trial landscape spans a broad range of therapeutic modalities, patient populations, and endpoint frameworks — from early induction chemotherapy studies to contemporary perioperative immunotherapy designs. The trials summarized below reflect key design parameters relevant to understanding how pivotal studies in this space have been structured, including phase, comparator arms, primary endpoints, and notable results.

APG-157: Building on Positive Phase II Data in HNSCC

Recent clinical investigation in HNSCC has spanned neoadjuvant immunotherapy combinations, salvage regimens, and real-world analyses of established standards of care. The studies below represent a cross-section of meaningful efficacy and safety data informing current and emerging treatment strategies.

• Cadonilimab Neoadjuvant Study (NCT06023875): Thirty patients with locally advanced, resectable HNSCC received cadonilimab (PD-1/CTLA-4 bispecific antibody, 10 mg/kg) combined with docetaxel (75 mg/m²) and cisplatin (60 mg/m²) every 3 weeks for three cycles. Efficacy outcomes were notable: ORR 83.3%, DCR 100%, MPR rate 76.7%, and pCR rate 50.0%. All patients experienced treatment-related adverse events (TRAEs); Grade 3 TRAEs occurred in 23.3% of patients. PFS and OS data remained immature as of February 2025. Higher baseline M1-like macrophage infiltration in the tumor stroma was associated with improved treatment efficacy.

• NIVOTAX TTCC Study: This randomized, non-comparative, multicenter Phase II trial enrolled 141 platinum-ineligible patients with previously untreated recurrent/metastatic HNSCC. Patients received either paclitaxel (80 mg/m² weekly) plus nivolumab (240 mg biweekly) for 12 weeks followed by maintenance nivolumab q4 weeks (nivotax arm, n=93), or weekly cetuximab (250 mg/m²) for 12 weeks followed by maintenance cetuximab (Erbitax arm, n=48). The primary endpoint of 2-year OS was met: 24.7% (95% CI 15.9–33.5) with nivotax versus 13.4% (95% CI 3.6–23.2) with Erbitax. Median OS, PFS, and ORR were similar between arms, with no differences by age, PD-L1 CPS, or Karnofsky Performance Scale. Grade ≥3 TRAEs occurred in 38% (nivotax) and 43% (Erbitax); notably, treatment-related mortality was higher in the nivotax arm (18% vs. 8.3%), driven by a greater occurrence of respiratory adverse events.

• Neoadjuvant Chemoimmunotherapy Retrospective Study (2019–2024): This retrospective analysis included 82 HNSCC patients who underwent surgery following neoadjuvant chemoimmunotherapy, with oral cavity malignancies comprising 50% of cases. Nearly 39% of patients received two cycles of neoadjuvant therapy; the remainder received three or more. R0 resection was achieved in 95.1% of patients; ORR was 79.3%; pCR rate was 25.6% (95% CI 15.3%–35.1%); and MPR rate was 41.5% (95% CI 30.4%–52.0%). At a median follow-up of 16 months, 1-year DFS was 80.5% (95% CI 72.4%–88.6%) and 1-year OS was 93.7% (95% CI 88.7%–99.1%). All patients demonstrated good tolerance, with a Grade 3/4 TRAE rate of 14.6%.

• TPC Neoadjuvant Study (Memorial Sloan Kettering, 1990–2023): Fifty-six HNSCC patients received neoadjuvant taxane, platinum, and cetuximab (TPC) prior to definitive therapy. Pathologic ORR was 71% for the primary tumor and 61% overall (primary and lymph nodes); pCR plus pNCR rate was 29% for primary tumors and 20% overall. Radiographic response prior to definitive surgical treatment was 88%. Primary tumor pORR was associated with significantly improved DFS (P=0.001) and OS (P=0.040); overall pORR was associated with improved DFS (P=0.024) and a trend toward improved OS (P=0.145).

• EXTREME Regimen Real-World Study (Croatian centers, 2016–2022): This retrospective, multicenter study evaluated 217 patients with recurrent/metastatic HNSCC treated across six Croatian oncology centers. The majority (91%) received the EXTREME regimen (cetuximab with cisplatin/carboplatin and 5-fluorouracil). Median OS was 14 months (95% CI 12–17) and median PFS was 6.2 months (95% CI 6.0–7.2); ORR was 21% and disease control rate was 63%. Grade ≥3 toxicity occurred in 18.9% of patients, with no treatment-related deaths reported. Cetuximab-induced rash was correlated with longer PFS.

• MEMOCLUB Regimen Study (Taipei Veterans General Hospital, 2015–2022): This retrospective cohort study assessed the MEMOCLUB regimen (methotrexate, epirubicin, mitomycin-C, vincristine, cisplatin, leucovorin, 5-fluorouracil, and bleomycin), with or without cetuximab, in 124 patients with platinum-refractory recurrent/metastatic HNSCC. Median PFS was 2.9 months and median OS was 5.3 months; ORR was 10.5% and disease control rate was 27.4%. Cetuximab co-administration emerged as a significant prognostic factor for improved OS in both univariate and multivariate analyses, with cetuximab-naïve patients deriving the greatest survival benefit. Hematological toxicity was the most common adverse event, with anemia being most frequent; no cases of Grade 3 or higher mucositis were reported.

Advancing HNSCC Treatment with Novel Immunotherapy and ctDNA

The initiation of the AVTA 30-01 Phase III trial marks a significant step forward in the pursuit of more effective treatments for locally advanced head and neck squamous cell carcinoma (HNSCC). This global study, evaluating Aveta Biomics' oral immunotherapy APG-157, holds the promise of introducing a novel therapeutic class into a challenging disease setting. Preclinical research suggests APG-157 may enhance anti-tumor immunity, particularly in combination with immune checkpoint inhibitors, by increasing CD8+ T cells and modulating the tumor microenvironment. If these benefits translate to the clinic, APG-157 could offer a much-needed alternative or adjunct to current standards of care.

Crucially, the trial integrates Natera's Signatera circulating tumor DNA (ctDNA) test as a secondary endpoint. This personalized, tumor-informed assay has demonstrated its value across a spectrum of solid tumors, from gastrointestinal and lung cancers to melanoma and bladder cancer, for detecting molecular residual disease (MRD), monitoring recurrence, and assessing treatment response. Its inclusion in AVTA 30-01 aims to further validate its utility in HNSCC, where existing evidence already points to ctDNA positivity as an indicator of disease progression and inferior survival. This strategic move could solidify Signatera's role in guiding personalized management for HNSCC patients, potentially enabling earlier detection of recurrence or informing treatment intensification/de-escalation strategies.

However, the path to clinical success is not without its considerations. While ctDNA offers a powerful prognostic tool, its performance can vary, and some studies have noted limitations such as lower sensitivity or technical failures in certain contexts. The ultimate impact of APG-157 will hinge on its ability to demonstrate superior efficacy and a favorable safety profile in this large-scale trial. Should the trial succeed, it would not only provide a new treatment option for HNSCC but also further embed ctDNA monitoring as an indispensable component of precision oncology, driving a more informed and individualized approach to cancer care.